Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Lua i Stíl Chicago (17ú heag.)Eaton, C., J. Wells, I. Holen, P. Croucher, agus F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
Lua MLA (9ú heag.)Eaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
Rabhadh: Seans nach mbeach na luanna seo go hiomlán cruinn i ngach uile chás.